Analyst Price Targets — KALA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 30, 2025 1:32 pm | — | Mizuho Securities | $1.50 | $1.81 | TheFly | Kala Bio downgraded to Neutral from Outperform at Mizuho |
| September 17, 2025 10:19 am | — | H.C. Wainwright | $35.00 | $17.47 | TheFly | Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright |
| August 7, 2024 6:18 am | Yi Chen | H.C. Wainwright | $7.50 | $3.10 | TheFly | Kala Pharmaceuticals price target lowered to $15 from $18 at H.C. Wainwright |
| May 17, 2024 10:34 am | Yi Chen | H.C. Wainwright | $9.00 | $3.25 | TheFly | Kala Pharmaceuticals price target lowered to $18 from $21 at H.C. Wainwright |
| April 3, 2024 6:43 am | Yi Chen | H.C. Wainwright | $10.50 | $4.00 | StreetInsider | Kala Pharmaceuticals (KALA) PT Lowered to $21 at H.C. Wainwright |
Latest News for KALA
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller…
KALA BIO (NASDAQ: KALA - Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect KALA BIO to post earnings of ($6.00) per share for the quarter. Parties can find conference call details on the company's upcoming Q2 2026 earning report for the latest details
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KALA.
U.S. House Trading
No House trades found for KALA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.